Gubra A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 10:41:35 2026-04-22 am EDT			5-day change	1st Jan Change
332.00 ^DKK	-0.60%		-3.66%	-35.85%

Mar. 09	Gubra's partner AbbVie reports positive phase 1 results for ABBV-295	RE
Mar. 06	Gubra A/S, 2025 Pre Recorded Earnings Call, Feb 27, 2026

Published on 03/06/2026 at 05:06 pm EST

S&P Capital IQ

Presenter Speech
Emma Lange (Executives)

Markus. Let us first reflect on 2025, an astounding year for Gubra.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Mar. 09	Gubra's partner AbbVie reports positive phase 1 results for ABBV-295	RE
Mar. 06	Gubra A/S, 2025 Pre Recorded Earnings Call, Feb 27, 2026
Mar. 02	SEB Raises Target Price for Gubra to 535 Danish Kroner (525), Reiterates Buy	FW
Mar. 02	Goldman Sachs Lowers Price Target for Gubra to 429 Danish Kroner (461), Reiterates Neutral - BN	FW
Feb. 27	Gubra A/S, 2025 Earnings Call, Feb 27, 2026
Feb. 27	Gubra 2025 group operating profit at DKK 2.2 billion	RE
Feb. 27	Gubra A/S Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 26	Gubra submits clinical trial application for GUB-UCN2 in Germany	RE
Feb. 26	Gubra Submits Clinical Trial Application for First-In-Human Study of Lead Asset GUB-UCN2	CI
Feb. 23	DNB Carnegie Lowers Price Target for Gubra to 510 Danish Kroner (from 538), Reiterates Buy Recommendation	FW
Feb. 10	Gubra launches Gubra Ventures	RE
Feb. 10	Gubra Launches Gubra Ventures	CI
Feb. 10	Gubra Appoints Zoë Johnson as Head of Gubra Ventures	CI
Jan. 15	AbbVie: stepping up obesity treatments with an alternative approach to GLP-1
Jan. 14	AbbVie plans to build out its presence in obesity market	RE